Synergy of CD95 ligand and teniposide: No role of cleavable complex formation and enhanced CD95 expression

European Journal of Pharmacology

Volumn 341, Issue 2-3, 1998, Pages 323-328

  Winter, Stephan ^a   Roth, Wilfried ^a   Dichgans, Johannes ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; CD95; Glioma; Teniposide; Topoisomerase

Indexed keywords

DNA TOPOISOMERASE; LIGAND; TENIPOSIDE; TUMOR NECROSIS FACTOR;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; DNA DAMAGE; DNA REPAIR; DRUG SENSITIZATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TARGET CELL;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; DNA TOPOISOMERASES, TYPE II; DRUG SYNERGISM; FAS LIGAND PROTEIN; GLIOMA; HUMANS; MEMBRANE GLYCOPROTEINS; TENIPOSIDE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032509754     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01478-7     Document Type: Article

References (21)

1. Berger J.M., Gamblin S.J., Harrison S.C., Wang J.C. Structure and mechanism of DNA topoisomerase II. Nature. 379:1996;225-232.
2. Friesen C., Herr I., Krammer P.H., Debatin K.M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. 2:1996;574-577.
3. Kamesaki S., Kamesaki H., Jorgensen T.J., Tanizawa A., Pommier Y., Cossman J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 53:1993;4251-4256.
4. Kamikaseda K., Stavrou D., Fujui M. The enhanced antitumor activity of DNA topoisomerase II-trapping drugs by natural human tumor necrosis factor against human glioma cell lines in vitro. Oncol. Rep. 1:1994;735-741.
5. Leithäuser F., Dhein J., Mechtersheim G., Koretz K., Brüderlein S., Henne C., Schmidt A., Debatin K.M., Krammer P.H., Möller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor superfamily, in normal and neoplastic cells. Lab. Invest. 69:1993;415-429.
6. Morgavi P., Cimoli G., Ottoboni C., Michelotti A., Conte P., Parodi S., Russo P. Sensitization of human glioblastoma T98G cells to VP16 and VM26 by human tumor necrosis factor. Anticancer Res. 15:1995;1423-1428.
7. Müller M., Strand S., Hug H., Heinemann E.M., Walczak H., Hoffmann W.J., Stremmel W., Krammer P.H., Galle P.R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99:1997;403-413.
8. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 364:1993;806-809.
9. Rensing-Ehl A., Frei K., Flury R., Matiba B., Mariani S.M., Weller M., Aebischer P., Krammer P.H., Fontana A. Loco-regional Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25:1995;2253-2258.
10. Roth W., Fontana A., Trepel M., Reed J.C., Dichgans J., Weller M. Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol. Immunother. 44:1997;55-63.
11. Rowe T.C., Chen G.L., Hsiang Y.H., Liu L.F. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 46:1986;2021-2026.
12. Saas P., Walker P.R., Hahne M., Quiquerez A.L., Schnuriger V., Perrin G., French L., van Meir E.G., de Tribolet N., Tschopp J., Dietrich P.Y. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J. Clin. Invest. 99:1997;1173-1178.
13. Trepel M., Dichgans J., Malipiero U., Fontana A., Weller M. p53 gene transfer for malignant glioma: Influence on sensitivity to anti-cancer drugs. J. Neuro-Oncol. 30:1996;95.
14. Van Meir E.G., Kikuchi T., Tada M., Li H., Diserens A.C., Wojcik B.E., Huang H.J.S., Friedmann T., de Tribolet N., Cavenee W.K. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 54:1994;649-652.
15. Weller M. Genetic regulation and therapeutic modulation of apoptosis in human malignant glioma. Cell. Physiol. Biochem. 6:1996;376-380.
16. Weller M., Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T cell apoptosis, and the immune privilege of the brain. Brain Res. Rev. 21:1995;128-151.
17. Weller M., Frei K., Groscurth P., Krammer P.H., Yonekawa Y., Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94:1994;954-964.
18. Weller M., Malipiero U.V., Aguzzi A., Reed J.C., Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95:1995;2633-2643.
19. Weller M., Malipiero U., Rensing-Ehl A., Barr P., Fontana A. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 55:1995;2936-2944.
20. Weller M., Weinstock C., Will C., Wagenknecht B., Dichgans J., Lang F., Gulbins E. CD95-dependent T cell killing by glioma cells expressing CD95 ligand: More on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. Cell. Physiol. Biochem. 7:1997;282-288.
21. Weller M., Winter S., Schmidt C., Esser P., Fontana A., Dichgans J., Groscurth P. Topoisomerase I inhibitors for human malignant glioma. Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β-lapachone. Int. J. Cancer. 73:1997;1-8.